The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited

Prostate

Volumn 76, Issue 10, 2016, Pages 897-904

  Cremers, Ruben G ^a,b   Aben, Katja K ^a,c   van Oort, Inge M ^a   Sedelaar, J P Michiel ^a   Vasen, Hans F ^b   Vermeulen, Sita H ^a   Kiemeney, Lambertus A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Foundation for the Detection of Hereditary Tumours   (Netherlands)

^c The Netherlands Comprehensive Cancer Organisation   (Netherlands)

Author keywords

clinical characteristics; family history; hereditary prostate cancer; phenotype; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGISTRY; CONTROLLED STUDY; FAMILY HISTORY; FOLLOW UP; GENETIC SUSCEPTIBILITY; GLEASON SCORE; HEREDITARY PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SPORADIC PROSTATE CANCER; AGE; BLOOD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETIC PREDISPOSITION; GENETICS; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGISTER; SURVIVAL RATE;

AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; SURVIVAL RATE;

EID: 84960971165     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23179     Document Type: Article

References (20)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014; 64(1):9–29.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317(15):909–916.
3. Stichting Opsporing Erfelijke Tumoren en de Vereniging Klinische Genetica Nederland Werkgroep Klinische Oncogenetica. Erfelijke tumoren: Richtlijnen voor diagnostiek en preventie: Stichting Opsporing Erfelijke Tumoren en de Vereniging Klinische Genetica Nederland, Werkgroep Klinische Oncogenetica; 2010.
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384(9959):2027–2035.
5. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993; 150(3):797–802.
6. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 2010; 58(2):275–280.
7. Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Fitzgerald LM, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Wahlfors T, Tammela T, Schleutker J, Wiklund F, Gronberg H, Emanuelsson M, Carpten J, Bailey-Wilson J, Whittemore AS, Oakley-Girvan I, Hsieh CL, Catalona WJ, Zheng SL, Jin G, Lu L, Xu J, International Consortium for Prostate Cancer G, Camp NJ, Cannon-Albright LA. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet 2014; 133(3):347–356.
8. Cremers RG, Galesloot TE, Aben KK, van Oort IM, Vasen HF, Vermeulen SH, Kiemeney LA. Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer. Prostate 2015; 75(5):474–483.
9. Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schroder FH, Witjes JA, Vasen HF. Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 2008; 122(4):871–876.
10. Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I. Screening for familial and hereditary prostate cancer. Int J Cancer 2015. doi: 10.1002/ijc.29949. [Epub ahead of print].
11. Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998; 82(4):564–567.
12. Bratt O, Damber JE, Emanuelsson M, Gronberg H. Hereditary prostate cancer: Clinical characteristics and survival. J Urol 2002; 167(6):2423–2426.
13. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, McReynolds KM, Bradley KM, Saez B, Godino J, Navarrete S, Fuertes F, Murillo L, Polo E, Aben KK, van Oort IM, Suarez BK, Helfand BT, Kan D, Zanon C, Frigge ML, Kristjansson K, Gulcher JR, Einarsson GV, Jonsson E, Catalona WJ, Mayordomo JI, Kiemeney LA, Smith JR, Schleutker J, Barkardottir RB, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41(10):1122–1126.
14. National Institute for Health and Care Excellence. CG175: Prostate cancer: Diagnosis and treatment. NICE Clinical Guidelines. London: National Institute for Health and Care Excellence; 2014.
15. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95(2):281–286.
16. Hemminki K, Rawal R, Bermejo JL. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005; 113(2):312–315.
17. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Initiative CO-CRUG-E, Australian Prostate Cancer B, Oncology UKGPCSCBAoUSSo, Collaborators UKPS, Consortium P, Kote-Jarai Z, Easton DF. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45(4):385–391, 391e381–382.
18. Cremers RG, Galesloot TE, Aben KK, van Oort IM, Vasen HF, Vermeulen SH, Kiemeney LA. Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer. Prostate 2015; 75(5):474–483.
19. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; COGS (Collaborative Oncological Gene-environment Study) Consortium; GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46(10):1103–1109.
20. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007; 12:4101–4110.